Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
19 oct. 2022 08h00 HE
|
Certara
PRINCETON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)...
Polyimide Films Market is projected to reach USD 3.0 Billion by 2030, growing at a CAGR of 5.9%: Straits Research
03 août 2022 12h40 HE
|
Straits Research
New York, United States, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Polyimide Films are synthetic films that are frequently employed in applications subject to hostile conditions due to their operational...
Universe Pharmaceuticals INC Announces Strategic Alliance with Kitanihon Pharmaceutical Co., Ltd. to Address the Market Demand for Kampo Medicine and High-end Traditional Chinese Medicine
13 déc. 2021 08h30 HE
|
Universe Pharmaceuticals INC
Ji’an, Jiangxi, China, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on...
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions
23 juin 2021 19h00 HE
|
Certara
PRINCETON, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its...
Universe Pharmaceuticals INC Enters into Letter of Intent for Strategic Cooperation with Kitanihon Pharmaceutical Co., Ltd.
25 mai 2021 08h00 HE
|
Universe Pharmaceuticals INC
Ji’an, Jiangxi, China, May 25, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the...
Telixが日本で腎臓がん用画像診断薬の臨床治験を開始
29 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
メルボルン, オーストラリア および京都, 日本, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals...
Telix Pharmaceuticals to Launch Japanese Renal Cancer Imaging Study
29 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
17 déc. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
19 nov. 2018 08h00 HE
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients
13 juin 2018 02h30 HE
|
PledPharma AB
Stockholm, June 13, 2018. PledPharma AB and Solasia Pharma K.K. (Solasia) today announced that the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, following a meeting with PledPharma and...